A new large language model, LassoESM, has been developed to predict lasso peptide properties, enabling the acceleration of rational design for biomedical applications. The model was trained on thousands of lasso peptide sequences and demonstrated accurate prediction of various properties.
A cohort study found that 40% of GLP-1RA orders were not filled, with lower rates among Non-Hispanic Black and Hispanic patients. These disparities may be attributed to differences in insurance coverage, GLP-1RA use, or cost thresholds.
The study reveals why some peptides are more effective and why certain bacterial cells are more vulnerable to membrane disruption. The findings provide a mathematical equation to identify optimal properties for efficacy, opening the door to designing novel compounds against antibiotic-resistant bacteria.
A new study from the Hebrew University of Jerusalem suggests that the stability of alpha amino acid backbones led to their selection as the foundation for proteins. The research proposes an assembly-driven model for the origins of life, offering fresh insight into how chemistry shaped biology.
A binational study found nearly 6 in 10 US adults and 3 in 10 Japanese adults discontinued semaglutide within 12 months of treatment. Patients with established cardiovascular disease and chronic kidney disease had higher discontinuation rates, highlighting the need for alternative treatments.
Prior authorization for glucagon-like peptide-1 receptor agonists (GLP-1RAs) became near universal, leading to substantial out-of-pocket costs. Out-of-pocket costs for GLP-1RAs rose significantly from 2020 to 2025, affecting many high-cost drugs.
Metabolic bariatric surgery shows promise as a cost-effective weight loss option for class II and III obesity patients. The study found bariatric surgery resulted in greater weight loss compared to GLP-1 receptor agonists.
Researchers developed a novel biomaterial called elastin domain-derived protein (EDDP) that overcomes natural elastin limitations. EDDP promotes cell adhesion and growth, aiding tissue regeneration in damaged tissues like heart valves, blood vessels, or torn ligaments.
A systematic review and meta-analysis of 18 trials found GLP-1 RAs significantly improved glycemic and weight outcomes in children and adolescents with type 2 diabetes or obesity. However, gastrointestinal adverse effects warrant attention in long-term management.
Researchers found genetic peptides called alpha-defensins that shape gut bacteria, producing healthier microbiomes and reducing insulin resistance. This discovery suggests personalized treatments can be tailored to individual genes, offering new hope for addressing chronic diseases like obesity and diabetes.
A cohort study found GLP-1 RAs offer body mass index-dependent cardiovascular benefits and consistent kidney protection for type 2 diabetes patients. The study suggests BMI stratification is crucial for guiding treatment decisions.
Researchers at Penn Engineering introduced AMP-Diffusion, a generative AI tool that designed tens of thousands of new antimicrobial peptides with bacteria-killing potential. The most potent AMPs performed as well as FDA-approved drugs without detectable adverse effects.
Researchers at UCL successfully chemically linked amino acids to RNA under conditions that could have occurred on early Earth, a significant step towards understanding the origin of protein synthesis. The study demonstrates how RNA might have first come to control protein synthesis.
A retrospective cohort study found that GLP-1 receptor agonists may reduce overall cancer risk, including lower risks of endometrial and ovarian cancers, among patients with obesity or overweight. However, these medications may also increase the risk of kidney cancer, highlighting the need for longer-term follow-up.
Researchers have discovered that combining antimicrobial peptides from bees and frogs can prevent bacteria from mutating quickly, making them a promising alternative to traditional antibiotics. This finding could lead to safer disease control in livestock and agricultural settings.
Cohort study finds GLP-1 receptor agonist use associated with modestly increased risk of incident diabetic retinopathy; however, those with preexisting DR experience fewer sight-threatening complications. Regular screening and monitoring recommended for all T2D patients on GLP-1 RAs.
A study found that semaglutide and liraglutide use are associated with a higher risk of nonarteritic anterior ischemic optic neuropathy in older patients with type 2 diabetes. The GLP-1 receptor agonists showed varying levels of risk, with liraglutide posing the greatest threat.
Researchers developed a new AI model named BATMAN to improve T cell receptor therapy accuracy. The AI uses a vast database of over 22,000 TCR-peptide interactions to predict peptide binding and identify potential cancer treatments.
The Insilico Medicine recent summer updates webinar introduced new features and functional updates to the company's generative AI platform, including Generative Biologics, Chemistry42, PandaOmics, DORA, and PreciousGPT. These updates aim to accelerate drug discovery and advance life sciences research.
Researchers at the University of Ottawa have made a breakthrough in developing nanoparticles that not only deliver drugs but also contribute to treatment. Their proof-of-concept study shows that particles can be armed with therapeutic potential, revolutionizing the field of nanomedicine.
A recent study published in JAMA Network Open found that glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment was associated with reduced all-cause mortality among older patients with cancer and type 2 diabetes. The survival benefit persisted across various subgroups, including age, sex, and cancer type.
Researchers mapped the frequencies used by Staphylococcus bacteria to communicate, identifying a signal from another species as potent against MRSA. This alternative technique weakens bacterial ability to coordinate attacks on hosts without killing them.
A cohort study found that GLP-1RAs like semaglutide and tirzepatide lower risk of dementia, stroke, and all-cause mortality in adults with type 2 diabetes and obesity. The findings suggest potential neuroprotective benefits beyond glycemic control.
The article provides practical strategies for managing symptoms in patients receiving GLP-1 RAs, focusing on diet and physical activity interventions to support muscle and nutrient preservation. Lifestyle factors remain crucial in GLP-1 RA treatment for effective weight management.
A new study found significant reductions in medication use, symptoms, and procedural interventions with GLP-1 receptor agonist therapy for idiopathic intracranial hypertension. Further prospective studies are needed to confirm these findings.
A research team led by Professor Joongoo Lee successfully expanded ribosome range to produce ring-shaped backbones in proteins. This breakthrough could open doors to novel therapeutics and advanced biomaterials.
The use of GLP-1 receptor agonists among diabetes patients is associated with a higher risk of developing incident neovascular age-related macular degeneration. Further research is needed to understand the underlying mechanisms and trade-offs between benefits and risks.
GLP1-RA treatment is associated with improvements in quality of life, restrained eating, and emotional eating behavior. The treatment also provides reassurance regarding its psychiatric safety profile.
Researchers discovered 500 cryptic peptides found only in pancreatic tumors, which could be targeted by vaccines or engineered T cells to attack the cancer. The peptides were identified using immunopeptidomics and shown to slow down tumor growth in mice.
The study estimates that expanded Medicare coverage for GLP-1RAs would increase access to these treatments and reduce obesity-related comorbidities. However, this would come with substantial costs over a decade, projected at $8 billion, highlighting the need for further price reductions and cost-saving strategies.
Two previously unknown ribosome-arresting peptides (RAPs), PepNL and NanCL, were identified in E. coli, inducing translation arrest through a unique mini-hairpin conformation in the exit tunnel of the ribosome. This discovery provides valuable insights into deciphering the hidden genetic codes within polypeptide sequences.
Aspiro Therapeutics is advancing an innovative inhaled therapy for asthma and COPD using peptidomimetics based on CC16. The treatment aims to address the underlying mechanism driving respiratory conditions, providing a more effective option for patients.
Researchers identify CLE16 peptide as key molecule promoting symbiotic relationship between plants and beneficial soil fungi. Supplementing with this peptide or its fungal equivalent can enhance nutrient exchange and strengthen these traits in crops.
A meta-analysis of randomized clinical trials found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a statistically significant reduction in all-cause dementia. Cardioprotective glucose-lowering therapies, however, did not show an overall reduction in dementia risk.
A study found that spending on GLP-1 RAs increased from 2018 to 2023, with the largest growth rate between 2022 and 2023. The total spending on these medications exceeded $71 billion.
Researchers developed new AI models, InstaNovo and InstaNovo+, to vastly improve accuracy and discovery in protein science. These models excel in tasks such as de novo peptide sequencing, identifying microorganisms, and discovering novel peptides, with implications for personalized medicine, cancer immunology, and beyond.
A team of biologists has discovered an ancient neurohormone called bombesin that controls appetite in humans and other vertebrates. The study also found that bombesin-like neurohormones are present in starfish, revealing a common ancestor of appetite regulation dating back over half a billion years.
Scientists have discovered peptides that bind irreversibly to the transcription factor cJun, permanently blocking its action in cancer cells. The study uses a new screening platform technology and has shown promising results for developing new cancer treatments.
A study found no increased risk of suicidal events among adults taking GLP-1 receptor agonists for diabetes or obesity, but continued monitoring is warranted to identify at-risk patients. The findings ease concerns about these potential adverse effects, allowing extended use of GLP-1 RAs.
Researchers developed CeSPIACE, a 39-amino-acid peptide drug candidate that binds to the spike protein, blocking viral entry. It demonstrates strong binding to major SARS-CoV-2 variants and shows efficacy against multiple strains in vivo and in vitro experiments.
Researchers have developed a new method to deliver antibiotics directly into the bladder tissue, eliminating over 90% of bacteria from the bladder. The nanogel-based drug delivery system shows promise in treating UTIs and could potentially lead to an eventual cure.
A newly discovered peptide called BRP has been found to rival semaglutide (Ozempic) in suppressing appetite and reducing body weight. Unlike Ozempic, BRP acts through a separate metabolic pathway, activating different neurons in the brain, which may offer a more targeted approach to body weight reduction.
Researchers have developed a palladium-mediated reaction to precisely modify peptides and proteins, overcoming challenges in bioconjugation. The method targets dehydroalanine-containing peptides and proteins, enabling efficient synthesis of structurally unique peptides.
A new drug screening method developed by Tampere University has found biologically active molecules that target specific tissues, potentially solving delivery issues in cancer and brain diseases. The method uses phage display and microdialysis to identify peptides with tissue-homing and penetration capabilities.
Camille Bilodeau's project uses AI and molecular simulations to design peptide-covered surfaces for targeted applications, including new medicines, water desalination, and semiconductor manufacturing. Her research group aims to develop a rapid predictive tool to understand surface-water interactions of tethered peptides.
Scientists have identified peptides that can capture and hold microplastics, providing a potential solution for removing these tiny plastic particles from environments. The method combines biophysical modeling, molecular dynamics, quantum computing, and reinforcement learning to optimize the binding of plastics to the peptides.
Sodium-glucose cotransporter-2 inhibitors and GLP-1RAs show reduced risk of moderate/severe COPD exacerbations compared to dipeptidyl peptidase 4 inhibitors. This finding may inform glucose-lowering medication prescribing for patients with type 2 diabetes and active COPD.
A systematic review and network meta-analysis of 601 trials revealed that SGLT2 inhibitors were more cardioprotective in older adults, while GLP-1 receptor agonists offered greater benefits to younger patients. These findings suggest personalized treatment approaches for type 2 diabetes based on age and sex.
A cohort study found that patients without type 2 diabetes had higher discontinuation rates and lower reinitiation rates of GLP-1 receptor agonist therapy. Inequities in access and adherence to effective treatments exacerbate disparities in obesity.
The study found a significant increase in obesity drug prescriptions from 0.76 million in July 2017 to 1.5 million in February 2024, mirroring rising public online search activity for semaglutide and tirzepatide. This correlation highlights the real-time association between public awareness and prescription trends.
Researchers at Terasaki Institute develop lipopeptide hydrogels to deliver peptide-based cancer vaccines, demonstrating sustained release and enhanced immune cell uptake. The system shows promise in overcoming limitations of traditional peptide-based vaccines.
Researchers have developed a groundbreaking approach using specially designed peptides to improve drug formulations, significantly enhancing anti-tumor efficacy in leukemia models. The innovative method achieves high drug loadings and optimizes delivery to targeted areas, holding significant potential for treating various diseases.
Research from Edith Cowan University reveals camel milk contains more naturally occurring bioactive peptides than cow's milk, potentially providing anti-hypertensive properties and improving digestion. This hypoallergenic alternative has the potential to reduce cardiovascular disease risk and offer a viable option for those with dairy ...
A large population-based analysis found that genetic variants in the GLP1R gene are associated with cardiometabolic traits and behavioral changes, such as risk-taking behavior and anxiety. These findings suggest that any observed behavioral changes with GLP1RA medications are unlikely to be a direct result of the medication.
A large international study of GLP1-RA users and dipeptidyl peptidase-4 inhibitors (DPP-4i) found no evidence that GLP1-RA use is associated with an increased risk of thyroid cancer. The study, published in the Thyroid journal, analyzed data from 92,497 GLP1-RA users and 2,484,408 DPP-4i users.
Researchers at Children's Hospital of Philadelphia and Stanford University have developed a new immunotherapy platform called TRACeR-I, which can more accurately recognize a wide variety of surface proteins expressed by cancer cells. This improved recognition enables the body's own immune system to target cancer cells more effectively.
Adult obesity trends in the US have declined for the first time in more than a decade, according to recent data. The South region experienced the largest decreases in body mass index and obesity prevalence, despite also facing high COVID-19 mortality rates among obese individuals.
Researchers from Institute of Science Tokyo develop a new approach to produce four-stranded β-sheets with precisely controlled number of strands, overcoming challenges of fibril aggregation and isomeric variation. This breakthrough could advance biotechnology and nanotechnology applications.
Researchers found a powerful antioxidant in Deinococcus radiodurans that combines with manganese to protect against radiation damage. The discovery could lead to synthetic antioxidants tailored for human needs, protecting astronauts and preparing for radiation emergencies.
A new study developed an innovative approach to combat antibiotic-resistant bacteria by tagging them with a chimeric agent that activates the immune system towards them. This tagging technique helps the immune system recognize and eliminate elusive pathogens, offering a promising new direction for fighting drug-resistant infections.